Replies to post #130474 on Biotech Values

[mcbio]

BMY reports interim phase-2 data for all-oral regimen of BMS-790052 plus BMS-650032

Side effects aside, this data would appear to back up ACHN's prior assertions (item 3 of #msg-66070779 ) about an NS5A + PI potentially being enough for genotype 1b patients.

[genisi]

As I was looking for interferon-free regimen trials, in which HCV patients are stratified by IL-28b polymorphism status (regarding my question in #msg-73065850), I found that Bristol's all-oral regimen of BMS-790052 plus BMS-650032 phase III in Japanese patients with genotype-1b, is one such trial:

http://clinicaltrials.gov/ct2/show/NCT01497834?term=IL-28b&rank=14